BioSpace News Archive

Approval of Purdue’s Opioid Reversal Drug Nalmefene Gets Mixed Reviews

The FDA’s decision to approve Purdue’s drug Nalmefene earned mixed reactions, especially as the company is in the middle of lawsuits. Here’s what you need to know.

February 25, 2022

·

2 min read

·

Vanessa Doctor, RN

Business

Amicus SPAC Spin-Off Unravels, Spooling Layoffs and Restructuring

The agreement would have created a spin-off gene therapy company and merged it with ARYA IV to create a new, publicly-traded entity called Caritas Therapies.

February 25, 2022

·

3 min read

·

Hannah Chudleigh

Pictured: Red and white Lilly sign on building/Mic

FDA

Eli Lilly Diabetes Drug Notches Another Win in Competitive Space

Eli Lilly’s Jardiance scores expanded heart failure approval from the FDA and will now be available to all patients with heart failure to reduce the risk of death and hospitalization.

February 25, 2022

·

2 min read

·

Kate Goodwin

Drug Development

Three Companies Plan to Build on Gene Therapy’s Promise in 2022

Three genome editing companies, Intellia Therapeutics, Editas Medicine and uniQure, are each anticipating a bright 2022 as the promises of gene therapy continue to be realized.

February 25, 2022

·

5 min read

·

Alex Keown

Business

AbbVie Makes Moves to Increase Profits in 2022

Chicago-based AbbVie has been making major decisions with company-wide impacts. The therapeutic company appears to be making changes that will benefit its bottom line.

February 25, 2022

·

3 min read

·

Hayley Shasteen

Drug Development

CDC Revises Mask Recommendations Following Drop in COVID-19 Rates

The Centers for Disease Control and Prevention (CDC) revised its recommendations on wearing masks indoors to protect against COVID-19.

February 25, 2022

·

3 min read

·

Mark Terry

Drug Development

Green Lights and Setbacks: Clinical Trial Updates for Feb. 21-25

The FDA places holds, companies receive clearance for new studies and Pharma giants release new data in last week’s clinical trial news.

February 25, 2022

·

5 min read

·

Mark Terry

FDA

FDA Adjusts EUA Dosing On Evusheld To Fight Omicron

The latest EUA adjustment was based on findings that Evusheld might not be as active against certain subvariants of Omicron, but it could be if the dosage is increased.

February 25, 2022

·

2 min read

·

Vanessa Doctor, RN

Policy

Report: More than Half of U.S. Abortions Done with Pills

Studies from Guttmacher Institute found that 54% of all abortions in the United States in 2020 were done with pills instead of surgery, an increase from approximately 44% in 2019.

February 25, 2022

·

3 min read

·

Mark Terry

Seasonal Influenza Vaccine Market: The pediatrics segment dominated the market due to the high prevalence and incidence rate of influenza among children

The seasonal influenza vaccine market is expected to invite exponential growth on the back of the rising prevalence of influenza among a large chunk of the global populace.

February 25, 2022

·

7 min read